Skip to main content
Journal of Analytical Science and Technology

Table 4 Summary of pharmacokinetic parameters for larotrectinib in mice (mean ± SD, n = 3)

From: Development and validation of an LC-MS/MS method for monitoring larotrectinib, a tropomyosin-related kinase inhibitor, in mouse and human plasma and application to pharmacokinetic studies

Parameters

I.V. (5 mg/kg)

P.O. (10 mg/kg)

AUClast (ng·h/mL)

6354.73 ± 388.90

4026.00 ± 111.83

AUC∞ (ng·h/mL)

6503.94 ± 403.92

4908.76 ± 384.70

T1/2 (h)

1.74 ± 0.11

–

CL (L/h/kg)

0.77 ± 0.05

–

Vss (L/kg)

1.14 ± 0.08

–

MRT (h)

1.48 ± 0.01

4.70 ± 0.90

Tmax (h)

–

1.25 ± 0.66

Cmax (ng/mL)

–

1103.33 ± 70.95

Fa (%)

–

31.70 ± 0.88

  1. acalculated by \( F\left(\%\right)=\frac{{\mathrm{AUC}}_{\mathrm{PO}}}{{\mathrm{Dose}}_{\mathrm{PO}}}\times \frac{{\mathrm{AUC}}_{\mathrm{IV}}}{{\mathrm{Dose}}_{\mathrm{IV}}}\times 100\ \left(\%\right) \)
Back to article page